20 August 2026
Latham Advises KaliVir Immunotherapeutics on US$14 Million Series A Extension Financing
Advising firms
Deal team
3 lawyers named in this releaseThe named deal team is part of full access
Full access opens the named team, the stated value and what it measures, the client and the counterparties, each with the sentence it was taken from.
Stated terms
The stated value, client and counterparties is part of full access
Full access opens the figure exactly as the release prints it, what that figure measures, the client and the counterparties, each with the sentence it came from.